US-listed spine and orthopaedics business Orthofix Medical has hired Andres Cedron as chief legal officer, replacing Patrick Keran who was dismissed last year alongside CEO Keith Valentine and CFO John Bostjancic following an investigation for misconduct.

Cedron joins from US medical device maker Stryker Corporation, where he was vice president and corporate secretary, overseeing corporate governance, US Securities and Exchange Commission compliance, M&A and ESG matters. At Orthofix, he will oversee the legal department and provide guidance on a broad range of corporate and commercial matters.

Lewisville, Texas-based Orthofix produces spinal hardware, bone growth therapies and specialised orthopaedic solutions. It distributes its products in 60 countries around the world.

Massimo Calafiore, president and CEO of Orthofix, said: “With a broad breadth of experience in the medical device industry and legal transactions, Andres is the perfect fit for this important leadership role. His extensive understanding of our business and the overall market will be an asset in helping the company drive profitability and growth as we continue to power Orthofix’s transformation.”

Cedron arrives after 14 years with Stryker. He spent just under two years as corporate secretary, having previously been chief counsel for its medical surgery and neurotechnology group, its Latin America division and its Eastern Europe, Middle East and Africa division. He originally joined as a senior legal counsel and senior director of compliance. Prior to his time at Stryker, he was an associate in Hunton & Williams’ corporate group.


He said: “I am thrilled to join such a talented leadership team and organisation of dedicated employees. This is an exciting time for the company, and I look forward to helping Orthofix become an even stronger competitor in the market.”

The company’s chief ethics and compliance officer Puja Leekha has been standing in as interim CLO since Keran’s dismissal in September. Keran had only become Orthofix’s CLO in January last year following its merger with SeaSpine, where he had held the same role since 2015. He previously worked at Mast Therapeutics, where he was president and chief operating officer.